Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains
Open Access
- 4 June 2025
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (6) , e0013725
Abstract
This study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the Calgary biofilm device. Mature-phase biofilms of C. albicans , C. auris (clades I, II, III, IV ), and C. parapsilosis were exposed to a range of drug concentrations (0.12–128 µg/mL). Minimum Inhibitory Concentration (MIC) values for planktonic cells were ≤2 µg/mL for all strains; however, biofilm-associated MICs, minimum biocidal concentration (MBC), minimum biofilm eradication (MBEC), and minimum biofilm damaging concentration (MBDC) were significantly higher (2–4,119 times). Geometric mean (GM) of MBEC values indicated that MNGX had the highest antifungal activity within Candida species, with a GM-MBEC of 5.9 µg/mL. Despite its overall potency, MNGX was less effective against C. auris biofilms from clade IV strains, where IBF showed superior activity. While not the most potent agent overall, AMB induced the smallest fold-change increases (2- to 32-fold) in biofilm-associated states data compared to planktonic MICs. Conversely, CAS exhibited the lowest activity against Candida spp. biofilms. The eradication of C. auris and C. parapsilosis biofilms required substantially higher concentrations than C. albicans , with some agents, such as RZF and CAS, necessitating up to 42-fold increases in dosage. In conclusion, our in vitro model highlights the antibiofilm activity of novel antifungals against major Candida species, revealing significant differences in efficacy among species. MNGX demonstrated the highest activity, underscoring its potential as a promising candidate for the treatment of biofilm-related infections.Keywords
Funding Information
- BIOASTER (BA220)
This publication has 48 references indexed in Scilit:
- Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASMThe Lancet Infectious Diseases, 2025
- Functional redundancy in Candida auris cell surface adhesins crucial for cell-cell interaction and aggregationNature Communications, 2024
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and RezafunginDrugs, 2021
- Candida auris Infection and Biofilm Formation: Going Beyond the SurfaceCurrent Clinical Microbiology Reports, 2020
- Candida albicans biofilm growth and dispersal: contributions to pathogenesisCurrent Opinion in Microbiology, 2019
- A New Method for Determination of Minimum Biofilm Eradication Concentration for Accurate Antimicrobial Therapy2019
- Development and regulation of single- and multi-species Candida albicans biofilmsNature Reviews Microbiology, 2017
- Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilmsInternational Journal of Antimicrobial Agents, 2016
- The biofilm matrixNature Reviews Microbiology, 2010
- Microplate Alamar blue assay for susceptibility testing ofCandida albicansbiofilmsMedical Mycology, 2007